Vestal Point Capital, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001974915
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2024 · 58 positions · Total reported value $1.21B · Top-10 concentration 61.5% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 64.6% · 14 new · 20 cut · 19 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.5% · Prev Value $4.28B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -2.9% · vs SPY -5.1% · Latest Value $3.87B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q1 2024 13F filing, Vestal Point Capital, LP disclosed 58 equity positions with a combined reported value of $1.21B. The filing implies a focused portfolio: its ten largest positions account for 61.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2024 were CYTK ($150.74M), JAZZ ($132.46M), NBIX ($97.92M). By sector, the heaviest allocations are Health Care 82.0%, Industrials 0.4%. Versus the prior quarter, allocation shifted toward Health Care (+0.5pp) and away from Other (-1.0pp).
Versus the prior quarter, Vestal Point Capital, LP opened 14 new positions, trimmed 20 and fully exited 19, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 36% of names.
The largest new positions opened in Q1 2024 were ONC ($50.83M), NARI ($38.38M), ARGX ($19.69M).
Of the 19 positions fully exited versus the prior quarter, the largest were INBX ($58.14M), MRK ($43.61M), CBAY ($38.38M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2024)
- ONC BEONE MEDICINES LTD · $50.83M
- NARI INARI MED INC · $38.38M
- ARGX ARGENX SE · $19.69M
- TGTX TG THERAPEUTICS INC · $15.97M
- ATXS ASTRIA THERAPEUTICS INC · $15.48M
- BMRN BIOMARIN PHARMACEUTICAL INC · $15.28M
- ALPN ALPINE IMMUNE SCIENCES INC · $13.87M
- APLS APELLIS PHARMACEUTICALS INC · $13.23M
Fully Exited (vs previous quarter)
- INBX INHIBRX BIOSCIENCES INC · prev qtr: $58.14M
- MRK MERCK & CO INC · prev qtr: $43.61M
- CBAY CYMABAY THERAPEUTICS INC · prev qtr: $38.38M
- PCVX VAXCYTE INC · prev qtr: $32.97M
- VRDN VIRIDIAN THERAPEUTICS INC · prev qtr: $21.78M
- RVMD REVOLUTION MEDICINES INC · prev qtr: $20.79M
- BIIB BIOGEN INC · prev qtr: $19.41M
- EW EDWARDS LIFESCIENCES CORP · prev qtr: $17.16M
Insider Transactions (Form 4)
Latest Vestal Point Capital, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Vestal Point Capital, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 63 US equity positions with a combined value of $3.87B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-127682 (status: Approved), registered 2023-04-14
- Regulatory AUM (Form ADV): $5.47B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: vestalpoint.com
Portfolio Structure
- 63 positions · $3.87B reported value (Q3 2026)
- Top 10 holdings = 67.3% of reported value
- Largest position: ABVX (ABIVAX SA) at 10.1%
- Average position size: $61.44M
Sector Tilt
- Health Care 100.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 14 new, 22 added, 20 reduced, 19 exited
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.15M | $150.74M | 12.47% | Add | |
| 2 |
|
1.10M | $132.46M | 10.95% | Add | |
| 3 |
|
710.00K | $97.92M | 8.10% | Reduce | |
| 4 |
|
525.00K | $79.36M | 6.56% | Reduce | |
| 5 |
|
1.00M | $53.64M | 4.44% | Add | |
| 6 |
|
1.25M | $53.50M | 4.42% | Reduce | |
| 7 |
|
350.00K | $52.31M | 4.33% | Add | |
| 8 |
|
325.00K | $50.83M | 4.20% | New | |
| 9 |
|
800.00K | $38.38M | 3.17% | New | |
| 10 |
|
5.11M | $34.75M | 2.87% | Add | |
| 11 |
|
2.00M | $29.50M | 2.44% | Add | |
| 12 |
|
2.61M | $29.10M | 2.41% | Add | |
| 13 |
|
400.00K | $27.10M | 2.24% | Add | |
| 14 |
|
4.72M | $24.57M | 2.03% | Add | |
| 15 |
|
750.00K | $20.35M | 1.68% | Reduce | |
| 16 |
|
50.00K | $19.69M | 1.63% | New | |
| 17 |
|
400.00K | $17.22M | 1.42% | Add | |
| 18 |
|
1.05M | $15.97M | 1.32% | New | |
| 19 |
|
1.10M | $15.48M | 1.28% | New | |
| 20 |
|
175.00K | $15.28M | 1.26% | New | |
| 21 |
|
350.00K | $13.87M | 1.15% | New | |
| 22 |
|
1.03M | $13.79M | 1.14% | Add | |
| 23 |
|
455.00K | $13.65M | 1.13% | Add | |
| 24 |
|
225.00K | $13.23M | 1.09% | New | |
| 25 |
|
100.00K | $12.95M | 1.07% | New | |
| 26 |
|
210.00K | $12.81M | 1.06% | New | |
| 27 |
|
1.20M | $12.61M | 1.04% | Reduce | |
| 28 |
|
200.00K | $11.39M | 0.94% | New | |
| 29 |
|
725.00K | $10.67M | 0.88% | New | |
| 30 |
|
325.00K | $9.50M | 0.79% | New | |
| 31 |
|
25.00K | $8.14M | 0.67% | New | |
| 32 |
|
45.00K | $8.01M | 0.66% | New | |
| 33 |
|
655.00K | $7.77M | 0.64% | New | |
| 34 |
|
2.20M | $7.26M | 0.60% | New | |
| 35 |
|
100.00K | $6.96M | 0.57% | Add | |
| 36 |
|
100.00K | $6.91M | 0.57% | New | |
| 37 |
|
695.00K | $6.56M | 0.54% | Reduce | |
| 38 |
|
75.00K | $6.15M | 0.51% | New | |
| 39 |
|
4.50M | $6.08M | 0.50% | New | |
| 40 |
|
1.35M | $6.03M | 0.50% | New | |
| 41 |
|
800.00K | $5.87M | 0.49% | Reduce | |
| 42 |
|
600.00K | $5.59M | 0.46% | New | |
| 43 |
|
1.20M | $5.58M | 0.46% | Add | |
| 44 |
|
15.00K | $5.19M | 0.43% | New | |
| 45 |
|
110.00K | $5.14M | 0.42% | New | |
| 46 |
|
800.00K | $4.98M | 0.41% | Reduce | |
| 47 |
|
130.00K | $4.19M | 0.35% | Hold | |
| 48 |
|
250.00K | $3.84M | 0.32% | New | |
| 49 |
|
175.00K | $2.74M | 0.23% | New | |
| 50 |
|
360.00K | $2.52M | 0.21% | Add | |
FAQ
What did Vestal Point Capital, LP buy in 2024-Q1?
In its 2024-Q1 13F filing, Vestal Point Capital, LP reported 58 equity positions worth $1.21B in aggregate; its largest disclosed positions were CYTK ($150.74M), JAZZ ($132.46M), NBIX ($97.92M).
How large is Vestal Point Capital, LP's portfolio?
Vestal Point Capital, LP reported $1.21B of long equity holdings across 58 positions as of 2024-Q1. Top-10 holdings account for 61.5% of reported value.
What is Vestal Point Capital, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.